Janux Therapeutics (JANX) News Today $36.01 -1.16 (-3.12%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$36.51 +0.50 (+1.37%) As of 02/21/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Lester Murray Antman dba SimplyRichLester Murray Antman dba SimplyRich raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 205.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,315 shares of the company's stock aftFebruary 12, 2025 | marketbeat.comAnalysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $89.90February 12, 2025 | americanbankingnews.comabrdn plc Invests $3.43 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)abrdn plc purchased a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 64,072 shares of the company's stock, valued at approximately $3,430,000.February 10, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Buy" by BrokeragesShares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been given an average recommendation of "Buy" by the thirteen ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, ten have given a buy recommendatiFebruary 9, 2025 | marketbeat.comInsider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells 3,334 Shares of StockFebruary 6, 2025 | insidertrades.comJanux therapeutics' chief business officer sells shares worth $140,999February 5, 2025 | msn.comJanux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $140,994.86 in StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $3,473,658.31. This trade represents a 3.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.February 5, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Up 6.9% - Should You Buy?Janux Therapeutics (NASDAQ:JANX) Trading 6.9% Higher - Here's What HappenedFebruary 5, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading Down 4.2% - What's Next?Janux Therapeutics (NASDAQ:JANX) Trading Down 4.2% - Should You Sell?February 4, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Janux Therapeutics Inc (JANX), Sun Pharmaceutical Industries Limited (IN:SUNPHARMA)February 4, 2025 | markets.businessinsider.comJanux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Up 19.8% in JanuaryJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 7,680,000 shares, a growth of 19.8% from the December 31st total of 6,410,000 shares. Currently, 16.4% of the shares of the stock are short sold. Based on an average daily volume of 1,050,000 shares, the days-to-cover ratio is currently 7.3 days.February 2, 2025 | marketbeat.comNisa Investment Advisors LLC Trims Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)Nisa Investment Advisors LLC lessened its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 41.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,867 shares of the company's stock afterJanuary 29, 2025 | marketbeat.comJanux Therapeutics names Zachariah McIver, D.O., Ph.D. as Chief Medical OfficerJanuary 25, 2025 | markets.businessinsider.comJanux Therapeutics Names McIver as Chief Medical OfficerJanuary 24, 2025 | marketwatch.comJanux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical OfficerJanuary 24, 2025 | businesswire.comJanux Therapeutics (NASDAQ:JANX) Shares Up 6.2% - Here's WhyJanux Therapeutics (NASDAQ:JANX) Shares Up 6.2% - What's Next?January 23, 2025 | marketbeat.comAnalysts Offer Predictions for JANX FY2025 EarningsJanux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Janux Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will pJanuary 22, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Up 19.8% in DecemberJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 7,680,000 shares, an increase of 19.8% from the December 15th total of 6,410,000 shares. Based on an average daily trading volume, of 1,050,000 shares, the short-interest ratio is currently 7.3 days. Currently, 16.4% of the company's stock are short sold.January 19, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading Down 3.5% - Time to Sell?Janux Therapeutics (NASDAQ:JANX) Shares Down 3.5% - Here's What HappenedJanuary 17, 2025 | marketbeat.comJanux TherapeuticsJanuary 17, 2025 | forbes.comJanux Therapeutics (NASDAQ:JANX) Shares Down 3.5% - Time to Sell?Janux Therapeutics (NASDAQ:JANX) Trading Down 3.5% - Here's What HappenedJanuary 15, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by BrokeragesJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been given an average recommendation of "Buy" by the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have givenJanuary 15, 2025 | marketbeat.comJanux Therapeutics' (JANX) "Outperform" Rating Reaffirmed at William BlairWilliam Blair restated an "outperform" rating on shares of Janux Therapeutics in a research note on Friday.January 10, 2025 | marketbeat.comBuy Rating for Janux Therapeutics Amidst Competitive Landscape and Advancements in Masked T-cell EngagersJanuary 9, 2025 | markets.businessinsider.comInsider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells 5,000 Shares of StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) CEO David Alan Campbell sold 5,000 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer now directly owns 293,054 shares of the company's stock, valued at $17,583,240. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.January 8, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Down 6.8% - What's Next?Janux Therapeutics (NASDAQ:JANX) Stock Price Down 6.8% - Here's What HappenedJanuary 8, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading Up 7% - Still a Buy?Janux Therapeutics (NASDAQ:JANX) Shares Up 7% - Time to Buy?January 7, 2025 | marketbeat.comInsider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells 13,334 Shares of StockJanuary 4, 2025 | insidertrades.comAndrew Hollman Meyer Sells 13,334 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 13,334 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $4,507,788.32. This represents a 13.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.January 3, 2025 | marketbeat.comJanux Therapeutics Inc Ordinary SharesJanuary 3, 2025 | morningstar.comJanux Therapeutics CEO sells $1.4M in common stockDecember 30, 2024 | markets.businessinsider.comJanux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Up 43.1% in DecemberJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 6,410,000 shares, a growth of 43.1% from the November 30th total of 4,480,000 shares. Currently, 13.6% of the company's shares are short sold. Based on an average daily volume of 949,600 shares, the days-to-cover ratio is currently 6.8 days.December 30, 2024 | marketbeat.comLifesci Capital Upgrades Janux Therapeutics (NASDAQ:JANX) to Strong-BuyLifesci Capital upgraded Janux Therapeutics to a "strong-buy" rating in a report on Friday.December 28, 2024 | marketbeat.comDavid Alan Campbell Sells 25,000 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) StockDecember 28, 2024 | insidertrades.comJanux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells $1,404,750.00 in StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) CEO David Alan Campbell sold 25,000 shares of the stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total value of $1,404,750.00. Following the transaction, the chief executive officer now owns 217,054 shares of the company's stock, valued at approximately $12,196,264.26. This represents a 10.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.December 27, 2024 | marketbeat.comLifeSci Capital Initiates a Buy Rating on Janux Therapeutics Inc (JANX)December 27, 2024 | markets.businessinsider.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC raised its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 6.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 662,594 shares of the company's stock after purchasiDecember 27, 2024 | marketbeat.comWellington Management Group LLP Sells 29,436 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)Wellington Management Group LLP lessened its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 67.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,498 shares of the company's stock after selling 29,December 21, 2024 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of "Buy" from AnalystsShares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have earned an average recommendation of "Buy" from the twelve research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, ten have issued a buyDecember 21, 2024 | marketbeat.comState Street Corp Has $61.84 Million Position in Janux Therapeutics, Inc. (NASDAQ:JANX)State Street Corp cut its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 2.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,361,178 shares of the company's stock after selling 40,056 shares during the quarteDecember 19, 2024 | marketbeat.comBarclays PLC Purchases 144,883 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)Barclays PLC grew its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 496.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 174,061 shares of the company's stocDecember 18, 2024 | marketbeat.com20,674 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Bought by Neo Ivy Capital ManagementNeo Ivy Capital Management bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 20,674 shares of the company'December 12, 2024 | marketbeat.comNavigating 10 Analyst Ratings For Janux TherapeuticsDecember 11, 2024 | benzinga.comBTIG Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)December 11, 2024 | markets.businessinsider.comCharles Schwab Investment Management Inc. Raises Position in Janux Therapeutics, Inc. (NASDAQ:JANX)Charles Schwab Investment Management Inc. boosted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 202.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 234,191 shares of the company's stock afterDecember 10, 2024 | marketbeat.comPoint72 Asset Management L.P. Has $17.99 Million Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)Point72 Asset Management L.P. boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 190.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 395,875 shares of the company's stock after buying an additional 259,445December 7, 2024 | marketbeat.com13,500 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Bought by Polar Asset Management Partners Inc.Polar Asset Management Partners Inc. bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 13,500 sharDecember 7, 2024 | marketbeat.comJanux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 MillionDecember 6, 2024 | businesswire.comScotiabank Reaffirms Their Hold Rating on Janux Therapeutics Inc (JANX)December 5, 2024 | markets.businessinsider.comTD Cowen Remains a Buy on Janux Therapeutics Inc (JANX)December 5, 2024 | markets.businessinsider.com Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address JANX Media Mentions By Week JANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JANX News Sentiment▼0.000.60▲Average Medical News Sentiment JANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JANX Articles This Week▼04▲JANX Articles Average Week Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RVMD News Today LEGN News Today BBIO News Today AXSM News Today BPMC News Today TLX News Today ELAN News Today LNTH News Today NUVL News Today CYTK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JANX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
